Epidemic analysis reveals gender gaps and treatment cascade challenges, indicating urgent intervention needs.
Despite low human immunodeficiency virus (HIV) prevalence in The Gambia (estimated adult prevalence 1.29% in 2024), the country faces a substantial burden, with approximately 25,000 people living with HIV, over 1,100 new infections, and approximately 1,200 acquired immunodeficiency syndrome (AIDS)-related deaths annually as of 2024. Gender disparities and treatment cascade gaps threaten Joint United Nations Programme on HIV/AIDS (UNAIDS) 2030 elimination targets. We examined 35-year epidemic trajectories (1990–2024), quantified gender-specific cascade performance and retention efficiency at critical transitions, and projected future scenarios under three intervention scenarios to inform national HIV strategies. We analyzed UNAIDS 2025 HIV data/estimates for The Gambia (1990–2024) for people living with HIV (PLHIV), new HIV infections, AIDS-related deaths, and prevalence by sex. Annual percent change (APC) was calculated using log-linear regression across epidemic phases. Treatment cascade performance was assessed through cascade achievement, retention efficiency, and gaps to UNAIDS 95-95-95 targets. Future trajectories (2025–2030) were projected under status quo, optimistic (10% improvement), and pessimistic (10% deterioration) scenarios. PLHIV increased from 1,035 (95% UI: 426-1,807) in 1990 to 25,247 (19,689 − 31,811) in 2024, with phases of early expansion (+ 31% annually, 1990–1999), peak transmission (+ 6%, 2000–2009), treatment scale-up (+ 1%, 2010–2019), and decline (-1%, 2020–2024). Women comprised 61% of PLHIV by 2024, with female-to-male prevalence ratio rising from 1.06 to 1.57. The 2024 treatment cascade (64% diagnosed, 44% on ART, 35% virally suppressed) fell below UNAIDS 95-95-95 targets. Male disadvantage emerged across stages: diagnosis (53% vs. 72% women, 19pp gap), ART coverage (27% vs. 55%, 28pp gap), and viral suppression (21% vs. 44%, 23pp gap). ART initiation was the main cascade bottleneck: 51% of diagnosed men versus 76% of women-initiated treatment (p < 0.001), while suppression rates on ART were similar (78% vs. 80%, p = 0.089). Projections to 2030 showed infections decreasing 6% to 1,055 under status quo, declining 27% to 826 under optimistic scenarios (preventing 1,374 infections), or increasing 13% to 1,265 under pessimistic scenarios, highlighting intervention fragility. The Gambian HIV epidemic shows a demographic decline, driven by deaths exceeding new infections rather than treatment-mediated viral suppression with persistent gender gaps. ART initiation remains the main bottleneck, with only 51% of diagnosed individuals starting treatment, particularly men. Meeting UNAIDS 2030 targets requires male-targeted testing, same-day ART initiation, and gender-stratified monitoring. A 10% annual improvement in prevention and cascade performance is needed to prevent 1,374 infections by 2030. Not applicable.
No takes yet. Share an insight, caveat, or question.
Barrow et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: